This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Bupropion Sustained Release for Bereavement: Results of an Open Trial

Sidney Zisook, Stephen R. Shuchter, Paola Pedrelli, Jeremy Sable, and Simona C. Deaciuc

Published: April 1, 2001

Article Abstract

Objective: The present study was conducted toassess whether DSM-IV-defined bereavement responds to bupropionsustained release (SR).

Method: Twenty-two subjects who had lost theirspouses within the previous 6 to 8 weeks and who met DSM-IVsymptomatic/functional criteria for a major depressive episodewere evaluated. Subjects completed the Hamilton Rating Scale forDepression (HAM-D), the Clinical Global Impressions scale, theTexas Revised Inventory of Grief, and the Inventory ofComplicated Grief at baseline and follow-up. Subjects weretreated with bupropion SR, 150 to 300 mg/day, for 8 weeks.

Results: Improvement was noted in bothdepression and grief intensity. For the intent-to-treat group,59% experienced a reduction of >= 50% on HAM-D scores. Thecorrelations between changes in the HAM-D scores and the griefscale scores were high, ranging from 0.61 (p = .006) to 0.44 (p =.054).

Conclusion: Major depressive symptoms occurringshortly after the loss of a loved one (i.e., bereavement) appearto respond to bupropion SR. Treatment of these symptoms does notintensify grief; rather, improvement in depression is associatedwith decreases in grief intensity. The results of this studychallenge prevailing clinical wisdom that DSM-IV-definedbereavement should not be treated. Larger, placebo-controlledstudies are indicated.

Volume: 62

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF